Tag: Life Attenuated Vaccines Market Forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Live Attenuated Vaccines Market Poised To Hit $41.1 Billion By 2030 With A 9.6% CAGR

The live attenuated vaccines market has experienced robust growth in recent years. It is forecast to grow from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The market’s past expansion is attributable to the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $41.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This anticipated rise during the projected timeframe stems from factors such as the increasing need for booster vaccinations, the emergence of infectious disease threats, the broadening of cold chain infrastructure, augmented global health financing, and advancements in next-generation vaccine technologies. Key developments expected during this outlook period encompass the expansion of national immunization initiatives, a rising need for childhood vaccinations, improvements in vaccine stability and storage methods, a heightened emphasis on readiness for pandemics, and the creation of multivalent vaccines.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=14241572&type=smp&name=Live%20Attenuated%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Growth Drivers: What’s Behind The Acceleration?

The expanding occurrence of infectious diseases is anticipated to boost the live attenuated vaccines market in the future. These diseases are conditions resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission directly or indirectly among individuals, animals, or environments. The surge in international travel intensifies the dissemination of infectious diseases, enabling pathogens to traverse borders more rapidly than control measures. Live attenuated vaccines play a crucial role in preventing infectious diseases by inducing a robust immune response using attenuated pathogens, thereby guaranteeing lasting immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body located in Switzerland, reported that in 2023, approximately 10.8 million individuals globally contracted TB, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

Live Attenuated Vaccines Market Segmentation: How Does The Market Break Down By Category?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Live Attenuated Vaccines Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the live attenuated vaccines market are concentrating on developing advanced products such as single-dose vaccines to improve immunization efficiency and enhance patient compliance. Single-dose vaccines deliver lasting immunity with just one shot, removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, boosting convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that develops vaccines for infectious diseases, revealed the launch of IXCHIQ, which gained approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This vaccine stands as the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. This approval carries significant weight because IXCHIQ is the world’s initial licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, and various other symptoms.

Live Attenuated Vaccines Market Competitive Overview And Top Companies

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

View The Full Live Attenuated Vaccines Market Report:

https://thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Live Attenuated Vaccines Market Poised To Hit $41.1 Billion By 2030 With A 9.6% CAGR

The live attenuated vaccines market has experienced robust growth in recent years. It is forecast to grow from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The market’s past expansion is attributable to the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $41.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This anticipated rise during the projected timeframe stems from factors such as the increasing need for booster vaccinations, the emergence of infectious disease threats, the broadening of cold chain infrastructure, augmented global health financing, and advancements in next-generation vaccine technologies. Key developments expected during this outlook period encompass the expansion of national immunization initiatives, a rising need for childhood vaccinations, improvements in vaccine stability and storage methods, a heightened emphasis on readiness for pandemics, and the creation of multivalent vaccines.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=14241572&type=smp&name=Live%20Attenuated%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Growth Drivers: What’s Behind The Acceleration?

The expanding occurrence of infectious diseases is anticipated to boost the live attenuated vaccines market in the future. These diseases are conditions resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission directly or indirectly among individuals, animals, or environments. The surge in international travel intensifies the dissemination of infectious diseases, enabling pathogens to traverse borders more rapidly than control measures. Live attenuated vaccines play a crucial role in preventing infectious diseases by inducing a robust immune response using attenuated pathogens, thereby guaranteeing lasting immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body located in Switzerland, reported that in 2023, approximately 10.8 million individuals globally contracted TB, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

Live Attenuated Vaccines Market Segmentation: How Does The Market Break Down By Category?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Live Attenuated Vaccines Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the live attenuated vaccines market are concentrating on developing advanced products such as single-dose vaccines to improve immunization efficiency and enhance patient compliance. Single-dose vaccines deliver lasting immunity with just one shot, removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, boosting convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that develops vaccines for infectious diseases, revealed the launch of IXCHIQ, which gained approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This vaccine stands as the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. This approval carries significant weight because IXCHIQ is the world’s initial licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, and various other symptoms.

Live Attenuated Vaccines Market Competitive Overview And Top Companies

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

View The Full Live Attenuated Vaccines Market Report:

https://thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Live Attenuated Vaccines Market Poised To Hit $41.1 Billion By 2030 With A 9.6% CAGR

The live attenuated vaccines market has experienced robust growth in recent years. It is forecast to grow from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The market’s past expansion is attributable to the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $41.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This anticipated rise during the projected timeframe stems from factors such as the increasing need for booster vaccinations, the emergence of infectious disease threats, the broadening of cold chain infrastructure, augmented global health financing, and advancements in next-generation vaccine technologies. Key developments expected during this outlook period encompass the expansion of national immunization initiatives, a rising need for childhood vaccinations, improvements in vaccine stability and storage methods, a heightened emphasis on readiness for pandemics, and the creation of multivalent vaccines.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=14241572&type=smp&name=Live%20Attenuated%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Growth Drivers: What’s Behind The Acceleration?

The expanding occurrence of infectious diseases is anticipated to boost the live attenuated vaccines market in the future. These diseases are conditions resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmission directly or indirectly among individuals, animals, or environments. The surge in international travel intensifies the dissemination of infectious diseases, enabling pathogens to traverse borders more rapidly than control measures. Live attenuated vaccines play a crucial role in preventing infectious diseases by inducing a robust immune response using attenuated pathogens, thereby guaranteeing lasting immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body located in Switzerland, reported that in 2023, approximately 10.8 million individuals globally contracted TB, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

Live Attenuated Vaccines Market Segmentation: How Does The Market Break Down By Category?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Live Attenuated Vaccines Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the live attenuated vaccines market are concentrating on developing advanced products such as single-dose vaccines to improve immunization efficiency and enhance patient compliance. Single-dose vaccines deliver lasting immunity with just one shot, removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, boosting convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that develops vaccines for infectious diseases, revealed the launch of IXCHIQ, which gained approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This vaccine stands as the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. This approval carries significant weight because IXCHIQ is the world’s initial licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, and various other symptoms.

Live Attenuated Vaccines Market Competitive Overview And Top Companies

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

View The Full Live Attenuated Vaccines Market Report:

https://thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Live Attenuated Vaccines Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Live Attenuated Vaccines Market Forecast: What Market Value Is Expected By 2030?

The market for live attenuated vaccines has experienced robust expansion over the past few years. Valued at $25.95 billion in 2025, it is projected to reach $28.52 billion by 2026, reflecting a compound annual growth rate of 9.9%. This historical growth can be linked to the worldwide impact of infectious diseases, governmental vaccination campaigns, policies mandating childhood immunization, vaccine administration within hospital settings, and vaccination initiatives spearheaded by the World Health Organization.

The market for live attenuated vaccines is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $41.11 billion, driven by a compound annual growth rate (CAGR) of 9.6%. This forecasted growth is fueled by factors such as the rising need for booster shots, the threat posed by new infectious diseases, improvements in cold chain logistics, enhanced global health investments, and the emergence of next-generation vaccine platforms. Key developments shaping this period include the broadening of national vaccination initiatives, increasing requirements for childhood immunizations, betterments in vaccine stability and preservation, a heightened emphasis on pandemic readiness, and the creation of multivalent vaccines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Live Attenuated Vaccines Market Development Factors: Which Trends Are Supporting Demand?

The rising occurrence of infectious diseases is anticipated to boost the expansion of the live attenuated vaccines market going forward. Infectious diseases refer to conditions caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between people, animals, or environments. The growth of international travel facilitates the swift spread of these illnesses, enabling pathogens to cross borders more rapidly than containment efforts can respond. Live attenuated vaccines are used to prevent infectious diseases by eliciting a strong immune response through weakened pathogens, providing durable immunity and curbing disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental body headquartered in Switzerland, reported that an estimated 10.8 million individuals contracted tuberculosis globally in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the heightened prevalence of infectious diseases is fueling the growth of the live attenuated vaccines market.

Live Attenuated Vaccines Market Segment Breakdown: Which Categories Generate The Most Revenue?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Live Attenuated Vaccines Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the live attenuated vaccines market are placing significant emphasis on the creation of advanced solutions, particularly single-dose vaccines, to boost immunization effectiveness and increase patient adherence. A single-dose formulation offers lifelong protection through just one injection, removing the necessity for repeated administrations. This approach makes vaccination more straightforward for both individuals and medical professionals, thereby improving ease of use and overall reach. A noteworthy example is Valneva SE, a biotech firm headquartered in France specializing in infectious disease vaccines, which introduced IXCHIQ in November 2023. This product secured approval from the U.S. Food and Drug Administration (FDA), an American health regulatory authority. IXCHIQ represents the first live-attenuated chikungunya vaccine globally, designed for individuals aged 18 and above. This regulatory milestone holds considerable importance as it marks the debut of a licensed vaccine for chikungunya, filling a critical gap in preventive care for this mosquito-borne viral illness, which is known to trigger intense fever, joint and muscle discomfort, along with other adverse effects.

Live Attenuated Vaccines Market Key Players And Strategic Industry Positioning

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Access The Complete Live Attenuated Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Live Attenuated Vaccines Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Live Attenuated Vaccines Market Through 2030?

The live attenuated vaccines market size has demonstrated robust growth in recent years. This market is projected to expand from $25.95 billion in 2025 to $28.52 billion in 2026, registering a compound annual growth rate (CAGR) of 9.9%. The historical growth can be attributed to factors such as the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market size is projected to experience substantial growth in the upcoming years. It will grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period can be attributed to factors such as demand for booster vaccinations, risks posed by emerging infectious diseases, expansion of cold chain infrastructure, increased global health funding, and advancements in next-generation vaccine platforms. Prominent trends throughout the forecast period include the expansion of national immunization programs, a rising demand for pediatric vaccination, improvements in vaccine stability and storage, a heightened focus on pandemic preparedness, and the ongoing development of multivalent vaccines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Important Drivers Are Powering The Live Attenuated Vaccines Market Growth?

An anticipated expansion in the live attenuated vaccines market is driven by the growing occurrence of infectious diseases. These diseases are characterized as illnesses stemming from detrimental microorganisms, including bacteria, viruses, fungi, or parasites, which possess the capability to transmit either directly or indirectly among individuals, animals, or environments. The escalating rate of international travel facilitates the accelerated dissemination of infectious diseases, enabling pathogens to traverse geographical boundaries more rapidly than current containment strategies can manage. Live attenuated vaccines play a crucial role in preventing infectious diseases by eliciting a robust immune reaction through attenuated pathogens, thereby guaranteeing sustained immunity and curbing the spread of illnesses. As an illustration, the World Health Organization, an intergovernmental body based in Switzerland, reported in March 2025 that an estimated 10.8 million individuals globally contracted TB in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the expanding incidence of infectious diseases is fueling the development of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Examined Through Segment Analysis?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Which Trends Are Supporting The Evolution Of The Live Attenuated Vaccines Market?

Leading companies within the live attenuated vaccines market are prioritizing the development of advanced products, such as single-dose vaccines, to boost immunization efficiency and improve patient adherence. These single-dose vaccines provide enduring immunity with just one injection, eliminating the necessity for multiple doses. This advancement simplifies the vaccination process for both patients and healthcare providers, thereby enhancing convenience and accessibility. For example, in November 2023, Valneva SE, a France-based biotech company focused on infectious disease vaccines, revealed the launch of IXCHIQ, which had received approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product is the world’s first live-attenuated chikungunya vaccine indicated for adults aged 18 and older. This approval holds considerable importance as IXCHIQ marks the world’s first licensed vaccine for chikungunya, addressing a previously unmet medical requirement for protection against this mosquito-borne viral disease, which can lead to severe fever, joint and muscle pain, and various other symptoms.

Which Firms Are Competing In The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Access The Complete Live Attenuated Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Area Represents The Largest Portion Of The Live Attenuated Vaccines Market?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Live Attenuated Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Live Attenuated Vaccines Market Between 2026 And 2030?

The live attenuated vaccines market size has experienced significant growth in recent years. This market is anticipated to expand from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. The historical expansion can be attributed to factors such as the global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, and WHO vaccination programs.

The live attenuated vaccines market is poised for significant expansion in the coming years, with its size anticipated to reach $41.11 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This projected growth stems from several factors, including the rising demand for booster vaccinations, the risks posed by emerging infectious diseases, the expansion of cold chain infrastructure, increased global health funding, and the introduction of next-generation vaccine platforms. Notable trends expected during this period include the wider implementation of national immunization programs, an escalating demand for pediatric vaccinations, enhancements in vaccine stability and storage, a greater emphasis on pandemic preparedness, and the development of multivalent vaccines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Factors Are Contributing To The Growth Of The Live Attenuated Vaccines Market?

The expanding occurrence of infectious diseases is projected to drive the live attenuated vaccines market’s growth in the foreseeable future. These diseases are conditions resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which can be transmitted either directly or indirectly among individuals, animals, or from the environment. An increase in global travel intensifies the dissemination of infectious diseases, as it facilitates pathogens’ cross-border movement at a quicker rate than preventive measures can manage. Live attenuated vaccines are effective in preventing infectious diseases by eliciting a robust immune response through the use of attenuated pathogens, thereby providing enduring immunity and curtailing disease transmission. For example, the World Health Organization, an intergovernmental body based in Switzerland, reported in March 2025 that an estimated 10.8 million individuals contracted TB globally in 2023, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the heightened incidence of infectious diseases is fueling expansion in the live attenuated vaccines market.

Which Segment Classifications Are Used In The Live Attenuated Vaccines Market Segment Analysis?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

What Market Trends Are Affecting The Live Attenuated Vaccines Market?

Major companies operating within the live attenuated vaccines market are prioritizing the creation of advanced products, such as single-dose vaccines, to enhance immunization effectiveness and improve patient adherence. These single-dose vaccines provide enduring immunity from a solitary shot, thereby eliminating the requirement for multiple doses. This development simplifies vaccination procedures for both patients and healthcare providers, significantly enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company that manufactures vaccines for infectious diseases, announced the introduction of IXCHIQ, which had received clearance from the U.S. Food and Drug Administration (FDA), a US-based health agency. IXCHIQ represents the world’s first live-attenuated chikungunya vaccine, specifically indicated for adults aged 18 and older. This approval is notably significant because IXCHIQ stands as the world’s first licensed vaccine for chikungunya, thereby fulfilling an unmet medical need for protection against this mosquito-borne viral disease, known for causing severe fever, joint and muscle pain, among other symptoms.

Which Firms Are Contributing To The Live Attenuated Vaccines Market Ecosystem?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Get The Full Live Attenuated Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Region Is The Largest In The Live Attenuated Vaccines Market?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Live Attenuated Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Live Attenuated Vaccines Market Over The Period 2026–2030?

The live attenuated vaccines market has shown robust expansion in recent years. Its size is expected to climb from $25.95 billion in 2025 to $28.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. This historical surge can be attributed to several factors including the worldwide burden of infectious diseases, various government immunization initiatives, established childhood vaccination policies, effective hospital-based vaccine delivery, and comprehensive WHO vaccination programs.

The live attenuated vaccines market is poised for significant expansion in the coming years. It is forecasted to reach $41.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This expected growth throughout the forecast period stems from factors such as the demand for booster vaccinations, the threats of emerging infectious diseases, the extension of cold chain infrastructure, increased global health funding, and the advancement of next-generation vaccine platforms. Key developments anticipated during this time include the widening of national immunization programs, a growing need for pediatric vaccination, progress in vaccine stability and storage, an intensified focus on pandemic preparedness, and the innovation of multivalent vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Underlying Factors Are Accelerating The Growth Of The Live Attenuated Vaccines Market?

The increasing spread of infectious diseases is set to boost the live attenuated vaccines market in the future. These diseases are ailments caused by detrimental microbes like bacteria, viruses, fungi, or parasites, capable of transmitting from one individual, animal, or setting to another, either directly or indirectly. Growing international travel quickens the dissemination of infectious diseases, enabling pathogens to traverse boundaries more rapidly than efforts to contain them. Live attenuated vaccines play a role in preventing infectious diseases by eliciting a robust immune response through attenuated pathogens, guaranteeing lasting immunity and lessening disease transmission. For instance, in March 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2023, approximately 10.8 million individuals contracted TB globally, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising occurrence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Divided Into Its Major Segments?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

How Are Trends Transforming The Live Attenuated Vaccines Market Landscape?

Leading companies operating within the live attenuated vaccines market are focusing on developing advanced products, such as single-dose vaccines, to enhance immunization efficiency and improve patient compliance. Single-dose vaccines offer lasting immunity with just one shot, eliminating the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, thereby enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company specializing in vaccines for infectious diseases, announced the introduction of IXCHIQ, which secured approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product is the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. The approval is significant as IXCHIQ marks the world’s inaugural licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, which can lead to severe fever, joint and muscle pain, and other symptoms.

Who Are The Prominent Organizations Shaping The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Read the full live attenuated vaccines market report here:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Region Is Projected To Dominate The Live Attenuated Vaccines Market During The Forecast Period?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Live Attenuated Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Live Attenuated Vaccines Market Over The Period 2026–2030?

The live attenuated vaccines market has shown robust expansion in recent years. Its size is expected to climb from $25.95 billion in 2025 to $28.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. This historical surge can be attributed to several factors including the worldwide burden of infectious diseases, various government immunization initiatives, established childhood vaccination policies, effective hospital-based vaccine delivery, and comprehensive WHO vaccination programs.

The live attenuated vaccines market is poised for significant expansion in the coming years. It is forecasted to reach $41.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This expected growth throughout the forecast period stems from factors such as the demand for booster vaccinations, the threats of emerging infectious diseases, the extension of cold chain infrastructure, increased global health funding, and the advancement of next-generation vaccine platforms. Key developments anticipated during this time include the widening of national immunization programs, a growing need for pediatric vaccination, progress in vaccine stability and storage, an intensified focus on pandemic preparedness, and the innovation of multivalent vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Underlying Factors Are Accelerating The Growth Of The Live Attenuated Vaccines Market?

The increasing spread of infectious diseases is set to boost the live attenuated vaccines market in the future. These diseases are ailments caused by detrimental microbes like bacteria, viruses, fungi, or parasites, capable of transmitting from one individual, animal, or setting to another, either directly or indirectly. Growing international travel quickens the dissemination of infectious diseases, enabling pathogens to traverse boundaries more rapidly than efforts to contain them. Live attenuated vaccines play a role in preventing infectious diseases by eliciting a robust immune response through attenuated pathogens, guaranteeing lasting immunity and lessening disease transmission. For instance, in March 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2023, approximately 10.8 million individuals contracted TB globally, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising occurrence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Divided Into Its Major Segments?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

How Are Trends Transforming The Live Attenuated Vaccines Market Landscape?

Leading companies operating within the live attenuated vaccines market are focusing on developing advanced products, such as single-dose vaccines, to enhance immunization efficiency and improve patient compliance. Single-dose vaccines offer lasting immunity with just one shot, eliminating the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, thereby enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company specializing in vaccines for infectious diseases, announced the introduction of IXCHIQ, which secured approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product is the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. The approval is significant as IXCHIQ marks the world’s inaugural licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, which can lead to severe fever, joint and muscle pain, and other symptoms.

Who Are The Prominent Organizations Shaping The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Read the full live attenuated vaccines market report here:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Region Is Projected To Dominate The Live Attenuated Vaccines Market During The Forecast Period?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Live Attenuated Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Live Attenuated Vaccines Market Over The Period 2026–2030?

The live attenuated vaccines market has shown robust expansion in recent years. Its size is expected to climb from $25.95 billion in 2025 to $28.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. This historical surge can be attributed to several factors including the worldwide burden of infectious diseases, various government immunization initiatives, established childhood vaccination policies, effective hospital-based vaccine delivery, and comprehensive WHO vaccination programs.

The live attenuated vaccines market is poised for significant expansion in the coming years. It is forecasted to reach $41.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This expected growth throughout the forecast period stems from factors such as the demand for booster vaccinations, the threats of emerging infectious diseases, the extension of cold chain infrastructure, increased global health funding, and the advancement of next-generation vaccine platforms. Key developments anticipated during this time include the widening of national immunization programs, a growing need for pediatric vaccination, progress in vaccine stability and storage, an intensified focus on pandemic preparedness, and the innovation of multivalent vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Underlying Factors Are Accelerating The Growth Of The Live Attenuated Vaccines Market?

The increasing spread of infectious diseases is set to boost the live attenuated vaccines market in the future. These diseases are ailments caused by detrimental microbes like bacteria, viruses, fungi, or parasites, capable of transmitting from one individual, animal, or setting to another, either directly or indirectly. Growing international travel quickens the dissemination of infectious diseases, enabling pathogens to traverse boundaries more rapidly than efforts to contain them. Live attenuated vaccines play a role in preventing infectious diseases by eliciting a robust immune response through attenuated pathogens, guaranteeing lasting immunity and lessening disease transmission. For instance, in March 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2023, approximately 10.8 million individuals contracted TB globally, comprising 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising occurrence of infectious diseases is fueling the expansion of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Divided Into Its Major Segments?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

How Are Trends Transforming The Live Attenuated Vaccines Market Landscape?

Leading companies operating within the live attenuated vaccines market are focusing on developing advanced products, such as single-dose vaccines, to enhance immunization efficiency and improve patient compliance. Single-dose vaccines offer lasting immunity with just one shot, eliminating the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, thereby enhancing convenience and accessibility. For instance, in November 2023, Valneva SE, a France-based biotech company specializing in vaccines for infectious diseases, announced the introduction of IXCHIQ, which secured approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product is the world’s first live-attenuated chikungunya vaccine designated for adults aged 18 and older. The approval is significant as IXCHIQ marks the world’s inaugural licensed vaccine for chikungunya, addressing a previously unmet medical need for protection against this mosquito-borne viral disease, which can lead to severe fever, joint and muscle pain, and other symptoms.

Who Are The Prominent Organizations Shaping The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Read the full live attenuated vaccines market report here:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Region Is Projected To Dominate The Live Attenuated Vaccines Market During The Forecast Period?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Live Attenuated Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the live attenuated vaccines market from 2026–2035 with trusted insights from The Business Research Company

How much is the Live Attenuated Vaccines Market valued at in 2026, and what valuation is forecast for 2030?

The live attenuated vaccines market size has observed significant growth in recent years. It is anticipated to increase from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. This past growth can be attributed to the global burden of infectious diseases, governmental immunization campaigns, childhood vaccination policies, hospital-based vaccine provision, and World Health Organization (WHO) vaccination programs.

The live attenuated vaccines market is projected to experience robust expansion in the upcoming years. This market is forecast to reach a value of $41.11 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this anticipated growth include an increased demand for booster vaccinations, the emergence of new infectious disease risks, enhancements in cold chain infrastructure, augmented global health funding, and the development of next-generation vaccine platforms. Significant trends expected during this forecast timeframe encompass the broadening of national immunization initiatives, a rising need for pediatric vaccinations, improvements in vaccine stability and storage solutions, a heightened emphasis on pandemic readiness, and the progression of multivalent vaccine development.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Drivers Are Influencing The Growth Of The Live Attenuated Vaccines Market?

The escalating occurrence of infectious diseases is anticipated to boost the expansion of the live attenuated vaccines market going forward. Infectious diseases are ailments resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmitting directly or indirectly between individuals, animals, or environments. Enhanced global travel exacerbates the dissemination of infectious diseases, enabling pathogens to traverse boundaries more rapidly than containment efforts. Live attenuated vaccines contribute to preventing these diseases by eliciting a robust immune response through weakened pathogens, thereby guaranteeing lasting immunity and diminishing disease transmission. For instance, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the growth of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Organized Into Various Segments?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

What Upcoming Trends Are Likely To Define The Future Path Of The Live Attenuated Vaccines Market?

Leading companies operating within the live attenuated vaccines market are directing their efforts towards developing advanced products, such as single-dose vaccines, to improve immunization efficiency and enhance patient compliance. Single-dose vaccines offer lasting immunity with a single shot, thereby removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, increasing convenience and accessibility. For example, in November 2023, Valneva SE, a France-based biotech company specializing in vaccines for infectious diseases, announced the launch of IXCHIQ, which had received approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product represents the world’s first live-attenuated chikungunya vaccine specifically indicated for adults aged 18 and older. This approval holds significant importance as IXCHIQ is the world’s first licensed vaccine for chikungunya, addressing an unmet medical need for protection against this mosquito-borne viral disease, which is known to cause severe fever, joint and muscle pain, and various other symptoms.

Who Are The Core Companies Influencing Trends In The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Regions Are Projected To Dominate The Live Attenuated Vaccines Market In The Coming Years?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Live Attenuated Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model